Methwani Disha Amar, Deosthale Nitin, Khadakkar Sonali, Dhote Kanchan, Harkare Vivek
Department of ENT, N. K. P. Salve Institute of Medical Sciences & Research Centre and Lata Mangeshkar Hospital, Nagpur, Maharashtra, India.
Int Arch Otorhinolaryngol. 2024 Jul 5;28(4):e597-e602. doi: 10.1055/s-0044-1786831. eCollection 2024 Oct.
The coronavirus disease 2019 (COVID-19), also referred to as the 2019 novel coronavirus, is caused by a single-stranded positive-sense RNA virus. This infectious agent spreads through respiratory routes, primarily utilizing aerosols. In our study, we shed light on ear, nose, and throat (ENT) manifestations, which can be considered as prognostic clinical biomarkers to reduce forthcoming complications among such critically ill patients. This makes it feasible for researchers to investigate or fetch early diagnosis in such cases with ease without the use of large, extensive hospital-base setups. To study the otorhinolaryngological (ENT) manifestations in symptomatic COVID-19 patients. From January to December 2021, a cross-sectional observational study was conducted at the Department of ENT of a tertiary care hospital in central India. All eligible symptomatic COVID-19 patients admitted to this institution during the study period were consecutively enrolled. The Institutional Ethics Committee gave its permission for the project. Out of the total of 1,375 patients, 78% of the patients diagnosed with COVID exhibited symptoms related to the ENT, while the remaining 22% did not display any ENT manifestations. Anosmia (71.2%), sore throat (55.62%), headache (44.3%), and loss of taste (66.3%) were among the most common ENT symptoms. The present study highlights ENT manifestations, which play a crucial role in the early diagnosis of COVID-19 patients, ensuring faster treatment and isolation for better containment of the disease. Symptomatic treatment has shown efficacy, but objective tests are needed to prevent overestimation, understand pathogenesis, and enhance treatment.
2019年冠状病毒病(COVID-19),也被称为2019新型冠状病毒,由一种单链正链RNA病毒引起。这种传染源通过呼吸道传播,主要利用气溶胶。在我们的研究中,我们揭示了耳鼻喉(ENT)表现,其可被视为预后临床生物标志物,以减少此类重症患者未来的并发症。这使得研究人员能够轻松地对此类病例进行调查或早期诊断,而无需使用大型、广泛的医院基础设置。
为了研究有症状的COVID-19患者的耳鼻喉科(ENT)表现。
2021年1月至12月,在印度中部一家三级护理医院的耳鼻喉科进行了一项横断面观察性研究。研究期间所有入住该机构的符合条件的有症状COVID-19患者均被连续纳入。机构伦理委员会批准了该项目。
在总共1375名患者中,78%被诊断为COVID的患者表现出与耳鼻喉相关的症状,而其余22%没有表现出任何耳鼻喉表现。嗅觉丧失(71.2%)、喉咙痛(55.62%)、头痛(44.3%)和味觉丧失(66.3%)是最常见的耳鼻喉症状。
本研究强调了耳鼻喉表现,其在COVID-19患者的早期诊断中起着关键作用,确保更快的治疗和隔离,以便更好地控制疾病。对症治疗已显示出疗效,但需要客观测试以防止高估、了解发病机制并加强治疗。